Eli Lilly
(NYSE:LLY) and Dexcom (NSDQ:DXCM) today announced a joint program for U.S. healthcare providers that includes Lilly’s new, rapid-acting Lyumjev mealtime insulin pen and Dexcom G6 continuous glucose monitoring (CGM) systems.
The program is designed to help clinicians use data to inform diabetes management, including promoting the benefits of a new mealtime insulin dose, the companies said in a news release. Lyumjev is a novel formulation of insulin lispro, which Lilly said was developed to speed the absorption of insulin into the bloodstream and reduce A1C levels in adults with diabetes.
Healthcare providers treating type 1 and type 2 diabetes will be able to assess their patients’ glucose levels and time in range with Dexcom G6 or Dexcom G6 Pro, either in blinded or unblinded mode, helping them quickly identify adult patients who struggle to manage their glucose levels following meals (postprandial glucose, or PPG), according to the companies. Postprandial glucose is often overlooked as a significant contributor to a patient’s average blood sugar level or A1C, according to a study published in 2019 by the American Diabetes Association.
Indianapolis-based Lilly and San Diego-based Dexcom are also promoting PPG monitoring as a component of diabetes treatment management. The companies announced a separate partnership in December.
“When it comes to treating diabetes, our partnership with Dexcom has the potential to be meaningful for (healthcare providers) who want to help their patients who may be struggling to manage their blood glucose levels after meals,” said Adrienne Brown, Lilly’s VP of U.S. diabetes and connected care. “Through this program, we can inspire confidence as clinicians and their patients evaluate new treatment options by showcasing how using these resources together can inform diabetes care.”
“We are thrilled to partner once again with a leader in diabetes care like Lilly,” said Rick Doubleday, chief commercial officer at Dexcom. “Our goal is that the real-time data provided through Dexcom G6 and Dexcom G6 Pro will allow healthcare providers to help their patients with diabetes make more informed decisions, measure and evaluate their time in range, and have more visibility to the potential benefits of transitioning to a new mealtime insulin such as Lyumjev.”
